Effect of Immunotherapy-infusion Time of Day on Survival of Patients with Advanced Cancers: a Study-level Meta-analysis

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2024 Jan 17

PMID 38232612

Authors

T Landre

A Karaboue

Z S Buchwald

P F Innominato

D C Qian

J B Assie

C Chouaid

F Levi

B Duchemann

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have become the standard of care for numerous malignancies. Emerging evidence suggests that the time of day (ToD) of ICI administration could impact the outcomes of patients with cancer. The consistency of ToD effects on ICI efficacy awaits initial evaluation.

Materials And Methods: This meta-analysis integrates progression-free survival (PFS) and overall survival (OS) data from studies with a defined 'cut-off' ToD. Hazard ratios (HRs) [95% confidence interval (CI)] of an earlier progression or death according to 'early' or 'late' ToD of ICIs were collected from each report and pooled.

Results: Thirteen studies involved 1663 patients (Eastern Cooperative Oncology Group performance status 0-1, 83%; males/females, 67%/33%) with non-small-cell lung cancer (47%), renal cell carcinoma (24%), melanoma (20%), urothelial cancer (5%), or esophageal carcinoma (4%). Most patients received anti-programmed cell death protein 1 or anti-programmed death-ligand 1 (98%), and a small proportion also received anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) (18%). ToD cut-offs were 13:00 or 14:00 (i.e. ICI median infusion time), for six studies, and 16:00 or 16:30 (i.e. reported threshold for weaker vaccination responses) for seven studies. Pooled analyses revealed that the early ToD groups had longer OS (HR 0.50, 95% CI 0.42-0.58; P < 0.00001) and PFS (HR 0.51, 95% CI 0.42-0.61; P < 0.00001) compared with the late ToD groups.

Conclusions: Patients with selected metastatic cancers seemed to largely benefit from early ToD ICI infusions, which is consistent with circadian mechanisms in immune-cell functions and trafficking. Prospective randomized trials are needed to establish recommendations for optimal circadian timing of ICI-based cancer therapies.

Citing Articles

Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing.

Goncalves L, Guedes H, Fortuna A, Lemos T, Gramaca J, Mourao N Cancers (Basel). 2025; 17(5).

PMID: 40075745 PMC: 11898965. DOI: 10.3390/cancers17050898.

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy.

Fey R, Billo A, Clister T, Doan K, Berry E, Tibbitts D Cancers (Basel). 2025; 17(5).

PMID: 40075580 PMC: 11899640. DOI: 10.3390/cancers17050732.

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.

Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing.

Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T In Vivo. 2025; 39(2):976-987.

PMID: 40010984 PMC: 11884485. DOI: 10.21873/invivo.13903.

Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study.

Huang Z, Karaboue A, Zeng L, Lecoeuvre A, Zhang L, Li X EBioMedicine. 2025; 113:105607.

PMID: 39983330 PMC: 11893323. DOI: 10.1016/j.ebiom.2025.105607.

References

Printezi M, Kilgallen A, Bond M, Stibler U, Putker M, Teske A . Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. Lancet Oncol. 2022; 23(3):e129-e143. DOI: 10.1016/S1470-2045(21)00639-2. View

de Bree L, Mourits V, Koeken V, Moorlag S, Janssen R, Folkman L . Circadian rhythm influences induction of trained immunity by BCG vaccination. J Clin Invest. 2020; 130(10):5603-5617. PMC: 7641012. DOI: 10.1172/JCI133934. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J Clin Oncol. 2023; 41(4):715-723. DOI: 10.1200/JCO.22.02270. View

Kemeny M, Alava G, Oliver J . Improving responses in hepatomas with circadian-patterned hepatic artery infusions of recombinant interleukin-2. J Immunother (1991). 1992; 12(4):219-23. DOI: 10.1097/00002371-199211000-00001. View

Iacobelli S, Garufi C, Irtelli L, Martino M, Santobuono F, Vicario G . A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. Am J Clin Oncol. 1995; 18(1):27-31. DOI: 10.1097/00000421-199502000-00006. View

Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C . Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses. Immunity. 2017; 46(1):120-132. PMC: 5263259. DOI: 10.1016/j.immuni.2016.12.011. View

Nobis C, Dubeau Laramee G, Kervezee L, De Sousa D, Labrecque N, Cermakian N . The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways. Proc Natl Acad Sci U S A. 2019; 116(40):20077-20086. PMC: 6778233. DOI: 10.1073/pnas.1905080116. View

Ince L, Barnoud C, Lutes L, Pick R, Wang C, Sinturel F . Influence of circadian clocks on adaptive immunity and vaccination responses. Nat Commun. 2023; 14(1):476. PMC: 9885059. DOI: 10.1038/s41467-023-35979-2. View

Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N . Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2023; 21(5):530-536. DOI: 10.1016/j.clgc.2023.06.004. View

10.

Keller M, Mazuch J, Abraham U, Eom G, Herzog E, Volk H . A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U S A. 2009; 106(50):21407-12. PMC: 2795539. DOI: 10.1073/pnas.0906361106. View

11.

Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P . Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J Immunother Cancer. 2024; 12(3). PMC: 10966813. DOI: 10.1136/jitc-2023-008011. View

12.

Feillet C, Krusche P, Tamanini F, Janssens R, Downey M, Martin P . Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci U S A. 2014; 111(27):9828-33. PMC: 4103330. DOI: 10.1073/pnas.1320474111. View

13.

Farshadi E, van der Horst G, Chaves I . Molecular Links between the Circadian Clock and the Cell Cycle. J Mol Biol. 2020; 432(12):3515-3524. DOI: 10.1016/j.jmb.2020.04.003. View

14.

Wang C, Lutes L, Barnoud C, Scheiermann C . The circadian immune system. Sci Immunol. 2022; 7(72):eabm2465. DOI: 10.1126/sciimmunol.abm2465. View

15.

Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M . Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus. 2023; 20(4):722-731. PMC: 10123478. DOI: 10.1007/s10388-023-01006-y. View

16.

Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S . Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Mol Cancer Res. 2022; 20(6):972-982. PMC: 9381128. DOI: 10.1158/1541-7786.MCR-21-0786. View

17.

Karaboue A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E . Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers (Basel). 2022; 14(4). PMC: 8870559. DOI: 10.3390/cancers14040896. View

18.

Son G, Chung S, Kim K . The adrenal peripheral clock: glucocorticoid and the circadian timing system. Front Neuroendocrinol. 2011; 32(4):451-65. DOI: 10.1016/j.yfrne.2011.07.003. View

19.

Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A . Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023; 182:107-114. DOI: 10.1016/j.ejca.2023.01.007. View

20.

Dizman N, Velazquez A, Duma N . Immune checkpoint inhibitors and timing of administration. Lancet Oncol. 2022; 23(2):e56. DOI: 10.1016/S1470-2045(22)00009-2. View